Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 1997

View Archived Issues

Interim phase III results reported for BCX-34

Sugen's angiogenesis inhibitor SU-5416 enters phase I

Genelabs Technologies reports phase III results from SLE trial

Cypros to start phase III trial for CABG

BioTime completes phase III trial with blood volume plasma extender

First long-term data for indinavir reported at ICAAC

Aastrom: Q4 and fiscal 1997 highlights

Techniclone: Q1 1997 highlights

Cortex: Q4 and fiscal 1997 highlights

Wakunaga prepares acidic fluoroquinolone

Novel antibacterial agents that inhibit bacterial two-component systems

R.W. Johnson identifies TCS inhibitor with potent antibacterial activity

Microcide identifies cephalosporin with excellent Gram-positive activity

Korean researchers present novel 3-isoxazolylvinylcephalosporins

Intracavernous moxisylyte recommended for first-line treatment of ED

OraVax to market and distribute Evans Medical's yellow fever vaccine

Effects of BQ-123 and BQ-788 on ET-1-induced corpus cavernosum contractions

Wyeth-Ayerst to promote Immunex's ENBREL in U.S.

L-Arginine not associated with objective improvement in organic ED

Linsidomine + moxisylyte for ED

ChemTrak reacquires rights to H. pylori test

Femara launched in U.S.

Regeneron and P&G joint development program for obesity

BioQuest acquires ICC

Abbott receives FDA clearance to market Gabitril

Neutralase proceeds to phase III trials

FDA clears Serevent Diskus